This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Apollo Endosurgery Résultats passés
Passé contrôle des critères 0/6
Informations clés
3.0%
Taux de croissance des bénéfices
21.2%
Taux de croissance du BPA
| Medical Equipment Croissance de l'industrie | 8.9% |
| Taux de croissance des recettes | 1.9% |
| Rendement des fonds propres | -122.2% |
| Marge nette | -51.8% |
| Dernière mise à jour des bénéfices | 31 Dec 2022 |
Mises à jour récentes des performances passées
Recent updates
Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?
Apr 03
Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?
Nov 30Is Apollo Endosurgery (NASDAQ:APEN) Using Too Much Debt?
Aug 05Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings
Aug 04Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?
Mar 02Is Apollo Endosurgery, Inc. (NASDAQ:APEN) Trading At A 20% Discount?
Aug 04Apollo Endosurgery: New Management Bounce Makes Weight Loss Specialist A Buy
Jun 28Is Apollo Endosurgery (NASDAQ:APEN) A Risky Investment?
May 05Apollo Endosurgery EPS beats by $0.05, beats on revenue
May 04A Look At The Intrinsic Value Of Apollo Endosurgery, Inc. (NASDAQ:APEN)
Mar 24What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?
Mar 03Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares
Feb 10We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt
Jan 31Assessing Apollo Endosurgery
Dec 27If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%
Dec 27Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?
Dec 01Apollo Endosurgery EPS beats by $0.10, beats on revenue
Nov 05Ventilation des recettes et des dépenses
Comment Apollo Endosurgery gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 22 | 77 | -40 | 57 | 12 |
| 30 Sep 22 | 72 | -41 | 53 | 11 |
| 30 Jun 22 | 68 | -36 | 50 | 11 |
| 31 Mar 22 | 66 | -28 | 47 | 10 |
| 31 Dec 21 | 63 | -25 | 43 | 10 |
| 30 Sep 21 | 60 | -18 | 39 | 9 |
| 30 Jun 21 | 56 | -14 | 35 | 8 |
| 31 Mar 21 | 45 | -17 | 28 | 7 |
| 31 Dec 20 | 42 | -23 | 28 | 8 |
| 30 Sep 20 | 41 | -26 | 31 | 8 |
| 30 Jun 20 | 40 | -32 | 34 | 8 |
| 31 Mar 20 | 48 | -35 | 41 | 9 |
| 31 Dec 19 | 51 | -27 | 42 | 10 |
| 30 Sep 19 | 54 | -39 | 44 | 11 |
| 30 Jun 19 | 57 | -40 | 45 | 13 |
| 31 Mar 19 | 58 | -40 | 45 | 13 |
| 31 Dec 18 | 61 | -46 | 46 | 12 |
| 30 Sep 18 | 62 | -35 | 46 | 11 |
| 30 Jun 18 | 64 | -30 | 47 | 10 |
| 31 Mar 18 | 66 | -27 | 47 | 9 |
| 31 Dec 17 | 64 | -27 | 47 | 8 |
| 30 Sep 17 | 64 | -33 | 44 | 9 |
| 30 Jun 17 | 63 | -36 | 44 | 9 |
| 31 Mar 17 | 63 | -41 | 43 | 8 |
| 31 Dec 16 | 65 | -41 | 42 | 8 |
| 30 Sep 16 | 66 | -36 | 43 | 7 |
| 30 Jun 16 | 66 | -38 | 44 | 8 |
Des revenus de qualité: APEN is currently unprofitable.
Augmentation de la marge bénéficiaire: APEN is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: APEN is unprofitable, but has reduced losses over the past 5 years at a rate of 3% per year.
Accélération de la croissance: Unable to compare APEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: APEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.1%).
Rendement des fonds propres
ROE élevé: APEN has a negative Return on Equity (-122.23%), as it is currently unprofitable.